University J Dent Scie 2026; Vol. 12, Issue 3

Applications of Immunohistochemistry in Dentistry



Dr. Nasir Ahmad Salati

Introduction:

The diagnostic methods of oral and maxillofacial pathology have undergone a profound change over the past few decades. Earlier, the classification of oral lesions relied on standard light microscopy utilizing routine Hematoxylin and Eosin (H&E) staining [UJDS]. While H&E remains the backbone of tissue diagnostics, the vast morphologic diversity and cellular resemblance found within head and neck pathology limits the visual acumen. Aggressive malignancies often mimic benign processes, and poorly differentiated tumors present varied appearance this making it difficult to predict the prognosis.

Application of Immuno-histochemistry: To bridge the gap between architectural morphology and molecular reality, immuno-histochemistry (IHC) has emerged as an important tool of modern dental oncology and oral maxillofacial research. By using the specificity of antigen-antibody binding, this laboratory technique allows oral pathologists to visually map, localize, and quantify precise cellular proteins, mutated receptors, and differentiation markers. Immunohistochemistry or IHC has been found effective in:

1. Oral Oncological Diagnostics:

a. Tumor Lineage Tracking: Resolving diagnostic paradoxes in aggressive tumors. For instance, differentiating primary Salivary Duct Carcinoma (SDC) from metastatic prostate adenocarcinoma by using prostate-lineage markers like Androgen Receptor (AR) and Prostate-Specific Antigen (PSA) against negative controls (p63/p40, CK5/6).

b. Squamous Cell Carcinoma (OSCC): Mapping microenvironments and cytokeratin profiles to access differentiation and aggressiveness in oral cancers.

II. Premalignancy & Tissue Fibrosis:

a. Oral Potentially Malignant Disorders (OPMDs): Investigating cellular transformation pathways. Active research focuses on markers like Osteopontin (OPN) to determine its dual role as an inflammatory/fibrotic mediator in Oral Submucous Fibrosis (OSF) and as a marker for malignant conversion into OSCC.

b. Basal Lamina Integrity: Mapping the breakdown of Collagen IV and laminin barriers to identify early micro-invasion before explicit structural degradation becomes visible via economic special stains.

III. Odontogenic Tumors and Cysts Classification:

Evaluating cell proliferation indexes via Ki-67 to predict the aggressive recurrence tendencies of Ameloblastomas and cysts including Odontogenic Keratocysts

Core Diagnostic Applications in Oral Pathology: The clinical application of IHC is broadly categorized into four major diagnostic and prognostic parameters:

1. Epithelial Malignancies & Premalignancy (OSCC & OPMDs)

Micro-Invasion Detection: In early Oral Squamous Cell Carcinoma (OSCC), mapping basement membrane integrity with antibodies against Collagen Type IV and Laminin reveals microscopic invasiom before visible stromal breakdown through routine H&E stains.

● **Malignant Transformation Prediction:** For Oral Potentially Malignant Disorders (OPMDs) like leukoplakia and erythroplakia, cell proliferation markers (Ki-

67) and tumor suppressor proteins (p53) help pathologically grade dysplasia and assess the statistical risk of transformation in malignancy.

- **Fibrosis & Progression Markers:** Markers like Osteopontin (OPN) are utilized in research to study structural progression in chronic conditions like Oral Submucous Fibrosis (OSF), both as a mediator of fibrosis and causing cellular atypia.

2. Salivary Gland Tumor Differentiating Panels:

Salivary gland neoplasms present some of the highest morphologic diversity in human pathology, making IHC panels mandatory for definitive diagnosis:

- **Lineage Architecture Mapping:** Differentiating between luminal cells (positive for Cytokeratins like CK7, CK8/18) and outer myoepithelial cells (positive for p63, p40, SMA, Calponin, and S-100).

- **The Prostatic Phenotype Paradox:** Distinguishing aggressive Salivary Duct Carcinoma (SDC) from other high-grade malignancies by identifying strong co-expression of the Androgen Receptor (AR) and Prostate-Specific Antigen (PSA).

- **Translocation Surrogates:** Utilizing targeted markers like PLAG1 (for Pleomorphic Adenoma) and CRTC1-MAML2 fusion indicators to differentiate various tumors.

3. Odontogenic Tumors and Cysts Classification:

Behavior Prediction: The Ki-67 cell proliferation index and PCNA expression matrices are used to identify biological aggression and high recurrence rates of Odontogenic Keratocysts (OKCs) and Ameloblastomas against other less aggressive cysts.

- Histogenetic Origin Tracking: Utilizing specific cytokeratin profiles (CK13, CK14, CK19) to know about the developmental rest populations (e.g., rests of Malassez, dental lamina).

4. Spindle Cell & Soft Tissue Tumors of the Oral Cavity:

When a mesenchymal tumor looks like as a poorly differentiated mass of spindle cells, IHC helps in determining the structural tissue origin.

Suspected Differentiation Pathway	Primary Positive IHC Biomarkers
Vascular / Endothelial (e.g., Kaposi Sarcoma, Hemangioma)	CD31, CD34, ERG, Factor VIII-Related Antigen
Muscle Origin (e.g., Leiomyoma, Rhabdomyosarcoma)	Desmin, Smooth Muscle Actin (SMA), Myogenin
Neural / Schwann Cell (e.g., Schwannoma, Neurofibroma)	S-100, SOX10
Melanocytic (e.g., Mucosal Melanoma)	HMB-45, Melan-A, SOX10

Conclusion:

The integration of immunohistochemistry (IHC) into oral and maxillofacial pathology has fundamentally bridged the historic divide between subjective architectural evaluation and precise molecular characterization. As demonstrated across diverse pathological processes ranging from early micro-invasion mapping in oral squamous cell carcinomas to complicated tumors like salivary duct carcinomas—IHC serves as an absolute diagnostic supplement in modern head and neck oncology. Merely relying on morphologic light microscopy can lead to diagnostic inaccuracy, which can be limited by deploying objective antibody-antigen matrices

References:

1. Bishop JA, Weinreb I, Swanson D, et al. GATA3 and TRPS1 are frequently positive in salivary duct carcinoma: diagnostic pitfalls with potential metastatic mimickers. Am J Surg Pathol. 2023;47(4):489–498.
2. Datar JV, Cooper K. The modern diagnostic matrix of myoepithelial markers in salivary gland pathology. Adv Anat Pathol. 2024;31(2):104–115.
3. Kujan O, Oliver RJ, Warnakulasuriya S. Immunohistochemical biomarkers in oral potentially malignant disorders: a systematic review of progressive transformation tracking. Oral Oncol. 2022;128:105822.
4. Speight PM, Farthing PM. The role of immunohistochemistry in the diagnosis of oral soft tissue tumors. Med Oral Patol Oral Cir Bucal. 2021;26(3):e321–e330.
5. Xu B, Wang L, Dogan S, et al. Androgen receptor expression and prostate-specific antigen co-expression in adenocarcinomas of the head and neck: a definitive lineage overview. Histopathology. 2024;84(3):412–424.
6. Carlos R, Sedano HO. The evolving cytokeratin profile matrix (CK13, CK14, and CK19) in developmental odontogenic cysts. J Oral Pathol Med. 2023;52(5):389–396
7. Nagao T, Licitra L, Loening T, et al. Salivary duct

carcinoma. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. WHO Classification of Head and Neck Tumours. 4th ed. Lyon: IARC Press; 2017. p. 173–174.

8. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific antigen in salivary duct carcinoma: an immunohistochemical study of 13 cases with clinical correlation. Am J Surg Pathol. 2000;24(4):579–586.

9. Williams L, Thompson LDR, Nakaguro M, et al. Salivary duct carcinoma with prostatic phenotype: diagnostic pitfalls and therapeutic markers. Head Neck Pathol. 2024;18(2):142–151

Address for Correspondence:
Dr. Nasir Ahmad Salati
M.D.S, PhD
Chairman/Chief Editor
Department Oral and Maxillofacial Pathology and Microbiology
Dr. Ziauddin Ahmad Dental College
Aligarh Muslim University, Aligarh
Email : nasalati.or@amu.ac.in

Access this article online
Website: www.ujds.in
DOI: .....